logo
logo
Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

NASDAQ•RYTM
CEO: Dr. David P. Meeker M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2017-10-09
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
連絡先情報
222 Berkeley Street, 12th Floor, Boston, MA, 02116, United States
857-264-4280
rhythmtx.com
時価総額
$6.84B
PER (TTM)
-34.3
19.5
配当利回り
--
52週高値
$122.20
52週安値
$45.91
52週レンジ
74%
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$51.30M+54.27%
直近4四半期の推移

EPS

-$0.82+15.49%
直近4四半期の推移

フリーCF

-$26.62M+5.58%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Product Revenue Soars 56% Net product revenue reached $137.5M for nine months, driven by increased sales volume across geographies.
Operating Loss Significantly Narrows Loss from operations improved 35% to $(145.0)M, reflecting lower R&D spending versus prior year.
R&D Costs Drop 36% R&D expense fell to $125.3M, primarily due to non-recurrence of IPR&D acquisition costs from 2024.
Strong Cash Position Maintained Cash and short-term investments totaled $416.1M as of September 30, 2025, supporting operations for over 24 months.

リスク要因

Need for Future Capital Continued operating losses require substantial future funding; failure to secure capital delays development or commercialization efforts.
IMCIVREE Market Acceptance Commercial success hinges on achieving broad coverage and adequate reimbursement from payors globally.
Regulatory Approval Uncertainty Future regulatory submissions, like the sNDA for acquired hypothalamic obesity, face inherent delays or adverse decisions.
IP Protection Challenges Patent validity and enforceability remain uncertain; competitors may develop non-infringing alternative technologies.

見通し

Advance Next-Gen Agonists Plan to complete RM-718 Phase 1 enrollment Q1 2026; initiate pivotal Phase 3 for bivamelagon in 2026.
Expand Global Commercialization Continue building sales infrastructure in Europe and pursuing market access in additional countries.
Awaiting Key FDA Decision Expect FDA decision on sNDA for acquired hypothalamic obesity by PDUFA date of December 20, 2025.
Manage Operating Expenses Expect SG&A to increase supporting expanded commercialization and ongoing clinical trial costs.

同業比較

売上高 (TTM)

Kiniksa Pharmaceuticals International, plcKNSA
$597.97M
+55.7%
Arvinas, Inc.ARVN
$312.30M
+93.9%
Protagonist Therapeutics, Inc.PTGX
$209.22M
-35.4%

粗利益率 (最新四半期)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
Arvinas, Inc.ARVN
100.0%
+0.0pp
Avidity Biosciences, Inc.RNA
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
RVMD$19.45B-19.8-49.2%7.0%
RNA$11.26B-18.3-37.7%2.3%
NUVL$7.43B-19.3-39.5%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
7.0%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月25日
|
EPS:-$0.79
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $51.30M+54.3%
    |
    EPS: $-0.82+15.5%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $48.50M+66.8%
    |
    EPS: $-0.75+41.5%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $32.70M+25.9%
    |
    EPS: $-0.81-65.5%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $130.13M+68.1%
    |
    EPS: $-4.34-35.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $33.25M+47.8%
    |
    EPS: $-0.71-6.6%
    予想を上回る

  • Form 10-Q/A - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月14日|
    売上高: $29.08M+51.3%
    |
    EPS: $-0.53-35.4%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|修正版データを参照

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $25.97M+126.4%
    |
    EPS: $-2.35+158.2%
    予想通り